Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intellia Therapeutics excels in CRISPR trials, faces regulatory challenges

Intellia Therapeutics showcased promising clinical trial results, a strong financial position, and a commitment to advancing CRISPR-based therapies. While facing regulatory and strategic challenges, the company is well-positioned to capitalize on opportunities in gene editing technologies and global trials.

Intellia Therapeutics advances CRISPR therapies with strong financials and global interest

Intellia Therapeutics is making significant progress in advancing their CRISPR-based therapies, with strong financials and promising global interest in their programs. Challenges include dose selection and trial specifics, while opportunities exist in data presentation, regulatory acceleration, and therapeutic approaches.

Intellia Therapeutics reports strong Q2 performance and eyes global expansion

Intellia Therapeutics reported strong financials, progress in clinical programs, and positive patient outcomes. Challenges include pending decisions and regulatory factors. Opportunities exist in expanding market reach and monitoring industry developments.

Intellia Therapeutics progresses with NTLA-2001, faces competition challenges

Intellia Therapeutics demonstrated significant progress in drug development with FDA clearance for Phase 3 trial of NTLA-2001 and positive interim data, supported by a strong financial position.
The company's adaptability, collaborations, and focus on efficacy position it well for future growth, despite challenges in understanding treatment benefits and addressing competition.
Opportunities lie in robust trial designs, potential synergies with RNA silencers, sustained financial support, and enhancing treatment outcomes and patient experience.
Analysts' interest in trial details and future prospects underscores confidence in Intellia's advancements and potential impact in the biotech industry.

Intellia Therapeutics excels in 2023, eyes CRISPR breakthroughs in 2024

Intellia Therapeutics had a strong financial year with a focus on advancing CRISPR-based therapies.
Confidence in pivotal study designs and collaborations present growth opportunities for the company.
Challenges include revenue adjustments and regulatory uncertainties that need to be navigated.
Overall, Intellia's strategic focus on genome editing and disease targets positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intellia Therapeutics (NTLA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Intellia Therapeutics (NTLA) Stock a Solid Choice Right Now?

Editas Medicine

Intellia Therapeutics and Editas Medicine are pre-revenue biotechs. Editas is a long way from commercializing its first medicine.

Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics

Beam Therapeutics

Ginkgo Bioworks Holdings

Guardant Health Inc

Guardant Health has tremendous opportunities in early cancer detection and cancer therapy selection. Beam Therapeutics and Intellia Therapeutics are pioneers in gene editing.

4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024

Intellia Therapeutics (NASDAQ: NTLA ) layoffs are a hot topic on Friday as the company prepares to cut jobs following an internal strategic review. According to a press release from Intellia Therapeutics, the company is reducing its total headcount by 15% to streamline operations.

Intellia Therapeutics Layoffs 2024: What to Know About the Latest NTLA Job Cuts

CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced its strategic priorities through 2026 and key anticipated 2024 milestones that support the company's mission to transform the lives of patients and bring forth a new era in medicine.

Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones

Archer Aviation

Cerus

Invitae

Verve Therapeutics

Cathie Wood's ARK Innovation ETF isn't afraid to go against Wall Street and the S&P 500. But in some cases, the consensus agrees with the famed ETF manager.

Analysts Agree These 8 Cathie Wood Stock Picks Will Soar In 2024

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a sickle-cell disease treatment, Casgevy, utilizing gene-editing technology developed by Vertex Pharmaceuticals Inc. NASDAQ: VRTX and CRISPR Therapeutics AG NASDAQ: CRSP.

2 gene-editing stocks reshaping hereditary disease treatments

Chewy

Etsy

Teladoc

These stocks are down but not out -- thanks to their solid long-term prospects. This list includes healthcare innovators and two exciting e-commerce companies.

5 Beaten-Down Stocks That Could Soar in 2024

The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.

3 Biotechs With Promising Gene Therapies in the Spotlight

Caribou Biosciences

CRISPR Therapeutics

Gene editing stocks have received a lot of attention throughout 2023. The intense focus on gene editing therapies and CRISPR technology is likely only to increase moving forward: The U.S. Food and Drug Administration (FDA) just approved the world's first medicine employing CRISPR technology.

3 Gene-Editing Stocks With the Potential to Mint Millionaires

Intellia and CRISPR Therapeutics both work in the field of gene editing. CRISPR Therapeutics just won regulatory approval for its first product, while Intellia recently entered late-stage development with its lead candidate.

Could Intellia Therapeutics Become the Next CRISPR Therapeutics?

ARK Genomic Revolution Multi-Sector ETF

Robinhood

Eli Lilly

Prime Medicine Inc

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Genomic medicine is predicted to become a multi-billion-dollar industry. Even so, this market will probably take years to mature, and risks abound as a result.

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.

Intellia Therapeutics and CRISPR Therapeutics are considered the top two players in the CRISPR space in the next 1 to 3 years. NTLA focuses on in vivo gene editing and has a comprehensive pipeline targeting various genetic diseases and conditions. CRSP focuses on ex vivo gene editing and has a diverse pipeline targeting different therapeutic areas, including hemoglobinopathies, immuno-oncology, and regenerative medicine.

CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics

Teladoc Health is roaring ahead on the path to profitability, making gains in EBITDA and free cash flow. One of Intellia Therapeutics' gene-editing candidates is entering late-stage studies, a step closer to product commercialization.

2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market

Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques. CRISPR-Cas9 is the most widely used gene editing technology, known for its simplicity and versatility. Major publicly traded CRISPR companies include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Beam Therapeutics, Caribou Biosciences, and Prime Medicine.

CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big

The European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises.

Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE Candidate

Intellia Therapeutics, Inc. enrollment completion for the phase 2 study using NTLA-2002 for the treatment of hereditary angioedema is expected in Q4 2023; Results expected in 2024. Pending positive feedback from regulators, potential to initiate a pivotal phase 3 study using NTLA-2002 for hereditary angioedema in Q3 of 2024. It is expected that the global hereditary angioedema market size is projected to reach $6.53 billion by 2025.

Intellia: Soon-To-Be Enrollment Completion Brings About Catalysts In 2024

CAMBRIDGE, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative single-dose therapeutics leveraging CRISPR-based technologies, today announced that the European Commission (EC) has granted orphan drug designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially life-threatening swelling attacks in people with HAE.

Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.

Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update

The fields of gene editing and gene therapy have been growing since the first draft of the human genome map was finished in 2003. In 2022, gaps in that map were completed.

3 Biotech Stocks That Are Betting on the Future of Gene Editing

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Ian Karp - SVP, IR and Corporate Communications John Leonard - President and CEO David Lebwohl - EVP and CMO Laura Sepp-Lorenzino - EVP and CSO Glenn Goddard - EVP and Chief Financial Officer Eliana Clark - EVP and CTO Conference Call Participants Kostas Biliouris - BMO Capital Markets Joon Lee - Truist Securities Mani Forooher - Leerink Partners Unidentified Analyst - Guggenheim Partners Dae Gon Ha - Stifel Maury Raycroft - Jefferies Gena Wang - Barclays Salveen Richter - Goldman Sachs Luca Issi - RBC Yanan Zhu - Wells Fargo Securities Greg Harrison - Bank of America Joseph Thome - TD Cowen Liisa Bayko - Evercore ISI Rick Bienkowski - Cantor Fitzgerald Terrence Flynn - Morgan Stanley Unidentified Analyst - Myles Minter Jay Olson - Oppenheimer Unidentified Analyst - Bernstein Silvan Tuerkcan - JMP Securities David Lebowitz - Citigroup Unidentified Analyst - Raymond James Operator Good morning and welcome to the Intellia Therapeutics' Third Quarter 2023 Financial Results Conference Call. My name is Drew and I will be your conference operator today.

Intellia Therapeutics, Inc. (NTLA) Q3 2023 Earnings Call Transcript

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the third quarter ended September 30, 2023.

Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today presented additional interim results from its ongoing Phase 1 study of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin (ATTR) amyloidosis. Results were presented in an oral presentation at the 4th International ATTR Amyloidosis Meeting, held Nov. 2–3 in Madrid, Spain.

Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting

The healthcare sector has produced several of the best-performing stocks since World War II. The secret to their outperformance has been their laser-like focus on innovation.

1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years

Intellia will soon start a phase 3 gene-editing trial, the first of its kind. Succeeding with the trial will not be the last hurdle it needs to overcome.

News for Intellia Therapeutics Stock (NTLA)